The global preimplantation genetic testing (PGT) market is projected to reach a value of US$552.7 million by 2025, expanding to US$999.2 million by 2032, with a compound annual growth rate (CAGR) of 8.8% during the forecast period. This steady market growth is driven by several factors, including advancements in reproductive technologies, rising infertility rates, and increased public awareness regarding genetic disorders. The growing reliance on in vitro fertilization (IVF) and advancements in genetic testing technology, such as next-generation sequencing (NGS) and improved embryo biopsy techniques, are further augmenting the market’s expansion. Increased awareness among parents about hereditary diseases, especially in light of delayed childbearing, has led to a surge in demand for preimplantation genetic testing.

Key Industry Highlights

The preimplantation genetic testing market is experiencing rapid evolution driven by the following key trends:

Rising infertility rates and delayed childbearing, particularly among women of advanced maternal age, are major contributors to market growth.

Technological advancements in genetic testing methods are continually improving the accuracy and reliability of PGT, enabling better IVF outcomes.

The integration of personalized medicine and precision genetic testing is opening new opportunities for market players to develop more targeted solutions.

Increased awareness about the benefits of genetic screening in fertility treatments and the prevention of hereditary disorders is creating more widespread adoption of PGT.

The increasing adoption of PGT in IVF procedures, particularly for aneuploidy screening (PGT-A), highlights its growing role in enhancing reproductive success. The market’s future growth is fueled by these technological and clinical advancements, making PGT an essential component of fertility treatments worldwide.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34757

Market Dynamics

Driver – Expanding Use of Assisted Reproductive Technologies (ART)

The expanding use of Assisted Reproductive Technologies (ART) is a primary driver behind the increasing demand for preimplantation genetic testing, especially in aneuploidy screening (PGT-A). As ART becomes more prevalent, PGT is integrated into IVF protocols to screen embryos for chromosomal abnormalities, increasing the likelihood of healthy pregnancies and reducing the risk of miscarriage. Data from the Centers for Disease Control and Prevention (CDC) indicates that ART cycles in the United States have steadily risen, contributing to greater utilization of genetic testing during these procedures. In 2020, U.S. fertility clinics performed over 326,000 ART cycles, and this number continued to increase in subsequent years, emphasizing the growing role of PGT in improving IVF success rates.

Restraint – Risk of Embryo Damage

Despite its significant advantages, preimplantation genetic testing faces some challenges, particularly related to the risk of embryo damage during the biopsy process. This procedure, which involves extracting cells from the embryo’s trophectoderm layer, is critical for genetic analysis but can lead to complications. Studies have shown that the biopsy process may increase the risk of pregnancy complications, such as preeclampsia and preterm birth. Additionally, diagnostic errors and false positives are concerns, as misclassifications of embryos can lead to the discarding of viable embryos. In some cases, such as a 2019 study, misclassifications of embryos resulted in healthy live births despite abnormal PGT-A results, adding further complexity to the widespread adoption of the technique.

Opportunity – Technological Advancements in Genetic Analysis

Technological innovations in genetic analysis present significant opportunities for enhancing the preimplantation genetic testing market. Next-generation sequencing (NGS) technologies have enabled high-resolution chromosomal analysis, resulting in higher pregnancy and live birth rates, particularly for women of advanced maternal age. Artificial intelligence (AI) and machine learning algorithms are also making substantial strides in embryo selection. For example, AI models such as convolutional neural networks (CNNs) have demonstrated high accuracy in predicting embryo viability, significantly improving IVF outcomes.

In addition, non-invasive genetic testing methods, including those based on cell-free DNA from spent culture media, are minimizing the risk of embryo damage while maintaining diagnostic accuracy. As these technologies continue to evolve, they offer substantial potential for reducing the cost of testing and enhancing the precision of genetic screening in IVF procedures.

Category-Wise Analysis

Product Insights

Kits are a dominant category in the preimplantation genetic testing market due to their ease of use, standardization, and ability to streamline the testing process. These kits, which include pre-validated reagents and optimized protocols, ensure consistent and reliable genetic analysis, reducing human error and enhancing clinical efficiency. The growing demand for IVF services is driving clinics to adopt these kits for their simplicity and scalability. The widespread availability of automated platforms that integrate seamlessly with testing kits further supports their increasing adoption across both developed and emerging healthcare markets.

Application Insights

Aneuploidy screening (PGT-A) is the largest application segment in the preimplantation genetic testing market, accounting for 41% of the total market share in 2024. The high prevalence of chromosomal abnormalities, particularly among women of advanced maternal age, is a significant factor driving the demand for this type of screening. PGT-A improves embryo selection by identifying chromosomal abnormalities, thus enhancing IVF success rates and reducing the risk of miscarriage. With the advent of advanced technologies, including next-generation sequencing, PGT-A has become a rapidly growing segment, with rising clinical acceptance and an increasing number of fertility clinics offering the service.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34757

Regional Insights

North America

North America holds the largest share in the global preimplantation genetic testing market, with the United States being a key contributor. The region benefits from high adoption rates of advanced reproductive technologies, increased awareness about genetic screening, and a strong presence of leading fertility clinics. Moreover, favorable reimbursement policies and significant investments in genetic research further support the region’s leadership in the PGT market. The rising prevalence of genetic disorders and the growing trend of delayed childbearing are also fueling demand for genetic testing in fertility treatments.

Europe

The European market for preimplantation genetic testing is expanding steadily, driven by increased adoption of IVF and growing awareness of genetic disorders. The United Kingdom, in particular, is poised for significant growth in the coming years, with projections indicating the highest CAGR in the region from 2025 to 2032. Technological advancements in genetic screening, along with strong regulatory support, are improving the accessibility and accuracy of PGT, contributing to its widespread use in fertility clinics across Europe.

Asia Pacific

The Asia Pacific region presents substantial growth opportunities for the preimplantation genetic testing market, driven by rising access to fertility treatments and an increasing incidence of genetic disorders. Countries such as China, India, and Japan are experiencing rapid urbanization and healthcare infrastructure improvements, which are boosting demand for advanced reproductive services. Moreover, government support for infertility treatments and the growing availability of affordable, locally manufactured testing kits are further accelerating market growth in this region.

Competitive Landscape

The preimplantation genetic testing market is highly competitive, with a mix of established diagnostic companies and emerging biotech firms driving innovation. Leading companies are focusing on technological advancements, particularly in NGS and AI-driven embryo analysis, to improve the accuracy and efficiency of PGT. Strategic mergers, acquisitions, and collaborations are common as companies seek to expand their product offerings and global reach. There is also significant competition in the development of user-friendly kits and automated platforms tailored to the needs of fertility clinics.

Key Industry Developments

In January 2025, Illumina, Inc. announced major upgrades to its NovaSeq X Series, incorporating advanced software and reagent kits to enhance genomic sequencing capabilities.
In September 2024, CooperSurgical launched an FDA-approved, single-hand-use inserter for Paragard®, a non-hormonal copper IUD, which demonstrates the company’s continued commitment to advancing reproductive healthcare solutions.

Key Players in the Preimplantation Genetic Testing Market

Key players in the preimplantation genetic testing market include:

Thermo Fisher Scientific, Inc.

CooperSurgical, Inc.

Illumina, Inc.

Abbott

Agilent Technologies, Inc.

Medicover Genetics

Revvity Inc.

Takara Bio Inc.

Genea BIOMEDX

SeraCare Life Sciences

Shiva Scientific Company

Future Outlook

The future outlook for the preimplantation genetic testing market remains promising, with continued technological advancements, increasing adoption of IVF, and a growing awareness of the benefits of genetic screening. As the market expands, innovations in non-invasive testing methods and AI-based embryo selection are likely to play a pivotal role in enhancing PGT’s accuracy, reducing costs, and improving overall IVF outcomes. The ongoing development of user-friendly testing kits and automated platforms will further drive adoption across both developed and emerging markets, ensuring sustained growth in the years ahead.